Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 976 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endothelial Clear all

Conditions: Sickle Cell Disease
Interventions: Oxypurinol, L-NMMA, Acetylcholine; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
Interventions: Ramucirumab, MEDI4736; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 7
States / cities: Santa Monica, California • Baltimore, Maryland • St Louis, Missouri + 4 more

Conditions: Endothelial Dysfunction, Vascular Diseases, Kidney Injury, Brain Disease, Vascular Inflammation
Interventions: Vericiguat, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Corneal Edema, Corneal Endothelial Dysfunction, Corneal Endothelial Dystrophy, Fuchs Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Bullous Keratopathy, Endothelial Dysfunction, Moderate Corneal Endothelial Decompensation
Interventions: EO2002, EO2002 low dose, EO2002 mid dose, EO2002 high dose; Biological
Lead sponsor: Emmecell; Industry
Eligibility: 21 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Greater Los Angeles, California • San Diego, California • Miami, Florida + 5 more

Conditions: Vascular Anomaly, Generalized Lymphatic Anomaly, Kaposiform Hemangioendothelioma, Kaposiform Lymphangiomatosis, Gorham-Stout Disease, Klippel Trenaunay Syndrome, Congenital Lipomatous Overgrowth, Vascular Malformations, and Epidermal Nevi
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Day and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2050
U.S. locations: 2
States / cities: Boston, Massachusetts • Cincinnati, Ohio

Conditions: MSI-H Colorectal Cancer
Interventions: Regorafenib, Pembrolizumab; Drug
Lead sponsor: Anwaar Saeed; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Proteinuric Renal Disease, Proteinuric Kidney Disease, Proteinuria, Proteinuria in Nephrotic Range
Interventions: sparsentan, No sparsentan; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fuchs' Endothelial Dystrophy
Interventions: Amphotericin B; Drug
Lead sponsor: Cornea Research Foundation of America; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Dietary Supplements
Interventions: Muscadine grape seed supplement; Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Healthy
Interventions: Besifloxacin Ophthalmic Suspension 0.6%; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Blood Pressure
Interventions: L-citrulline, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 14 Years to 40 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Menopause
Interventions: L-Citrulline, Placebo; Dietary Supplement
Lead sponsor: Texas Tech University; Other
Eligibility: 50 Years to 79 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Coronary Heart Disease
Interventions: Intermittent pneumatic compression of the lower extremities; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Vascular Diseases
Interventions: Fructose and physical inactivity; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Schizophrenia
Interventions: Folic Acid, Placebo; Dietary Supplement · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 90 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Post-traumatic Stress Disorder (PTSD), Cardiovascular Diseases, Autonomic Dysfunction, Vascular Stiffness, Nightmare, Endothelial Dysfunction, Veteran
Interventions: NightWare; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 22 Years to 88 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Coronary Artery Disease
Interventions: Febuxostat, Febuxostat placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Aging, Fragility, Endothelial Dysfunction
Interventions: Ischemic Conditioning; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 65 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Wauwatosa, Wisconsin

Conditions: Hypertension
Interventions: Effects of dark chocolate; Behavioral
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Oxidative Stress
Interventions: Herbs and spices, High fat meal; Other
Lead sponsor: Penn State University; Other
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Hypertension
Interventions: Inspiratory muscle strength training; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 50 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Healthy
Interventions: Controlled diet; Other
Lead sponsor: Janet Novotny; Federal
Eligibility: 25 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Beltsville, Maryland

Conditions: Sarcoma
Interventions: OMBRABULIN (AVE8062), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 6
States / cities: Santa Monica, California • Orlando, Florida • Maywood, Illinois + 3 more

Conditions: Atherosclerosis, Coronary Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery

Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema

Identification of Biomarkers for Patients with Vascular Anomalies

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections.

Muscadine Grape Seed Supplementation and Vascular Function

Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days

Oral L-Citrulline and ADMA in Pregnancy

Citrulline Supplementation On Vascular Responsiveness and Function in Postmenopausal Women

Global Vascular Effects of Intermittent Pneumatic Compression-Pilot Study

Vascular and Metabolic Consequences of Adopting a Westernized Lifestyle

Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects

NightWare and Cardiovascular Health in Veterans With PTSD

The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina

Ischemic Conditioning to Promote Microvascular Resiliency in Frail Individuals

Effects of Dark Chocolate on Insulin Sensitivity in People With High Blood Pressure

The Acute Effect of Spices on Vascular Health

Reduced Volume of Inspiratory Resistance Training

The Potential for Pomegranate Juice to Ameliorate Endothelial Dysfunction

A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies

Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme